FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Web-Presence will introduce the HeartCheck™ device to a global network of patients and affiliate organizations
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced an agency agreement with Arrhythmia Alliance based out of the United Kingdom. The Arrhythmia Alliance, operated under The Heart Rhythm Charity®, is a global coalition of independent charities, patient groups, patients, care givers, medical groups and allied professionals that work together under the Arrhythmia Alliance umbrella to promote timely and effective diagnosis and treatment of arrhythmias.
The agreement designates the Arrhythmia Alliance website as an authorized source for the purchase of the Company’s HeartCheck™ PEN. As a patient advocacy group and umbrella organization, the Arrhythmia Alliance promotion will reach thousands of registered people living with or caring for persons with arrhythmias such as atrial fibrillation (“AF”). With over 25,000 Arrhythmia Alliance members with AF, this will mark the largest focused introduction of the HeartCheck™ PEN and SMART Monitoring ECG service to the consumer arrhythmia market.
“The launch of this latest phase of our HeartCheck™ advertising campaign represents a significant opportunity for the introduction of the HeartCheck™ PEN into a large market of consumers who are specifically informed on the importance of managing arrhythmias and the importance of following the progression and/or treatment of AF in an effort to prevent stroke. This relationship meets our mutual objectives to provide an easy to use and validated arrhythmia monitoring solution to those people interested in the preservation of their health as well as those at risk for developing arrhythmia-based cardiac disease due to underlying conditions such as hypertension, diabetes, older age, familial histories and taking high risk medications,” said Etienne Grima, Chief Executive Officer for CardioComm Solutions.
Consumers purchasing the HeartCheck™ PEN ECG will have access to CardioComm Solutions’ SMART Monitoring ECG service, a free first ECG interpretation and the free GEMS™ Home software. The HeartCheck™ PEN is the only consumer device permitted by the US Food and Drug Administration (FDA) and Health Canada to display a person’s actual ECG tracing as an over-the-counter (OTC) consumer product. The HeartCheck™ PEN is also CE marked, allowing it to be sold within the European Union and other international locations that recognize FDA, CE and ISO regulatory compliance. The SMART Monitoring ECG service is capable of accepting ECGs from HeartCheck™ devices anywhere in the world with internet access and can return an interpreted ECG report within an average time of 30 minutes, 24/7. The device is also capable of storing and replaying up to 20 ECG recordings.
“We have come to know the HeartCheck™ PEN and CardioComm Solutions through their presence at international medical conferences and their participation in research projects. Providing individuals with an option for self-monitoring of their cardiac rhythm with added ability to capture and identify what arrhythmia may exist is important enough to have devices like the HeartCheck™ PEN featured as a life saving device on our membership website http://www.heartrhythmcharity.org.uk,” reported Trudie Lobban, Founder & Trustee of the Arrhythmia Alliance.
“We have established several advocacy-based relationships and intend to continue to expand awareness of the availability of our HeartCheck™ solutions and SMART Monitoring services through collaboration with recognized organizations such as the Arrhythmia Alliance. With material efforts invested in AF detection and awareness, CardioComm Solutions will now expand its program into the monitoring of arrhythmias in patients with congestive heart failure, and specifically, widening of the QRS complex as a risk factor for sudden cardiac death. It is exciting to be associated with an organization that can make such an impact on the health of so many,” closed Simi Grosman, member of the CardioComm Solutions Board of Directors.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of